EA Pharma Co., Ltd.
TransThera Sciences (Nanjing), Inc.

EA Pharma Co., Ltd. (President, Hidenori Yabune; Headquarters, Chuo-ku, Tokyo, Japan, "EA Pharma") and TransThera Sciences (Nanjing), Inc. (Chif Executive Officer, Funder Frank Wu, Headquarter Jiangbei New Area, Nanjing, China, “TransThera”) jointly announced to enter into a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (“GI”) system and liver.

Under the agreement, EA Pharma and TransThera will jointly dedicate research resources to the discovery and development of potential clinical candidates. The two companies will establish a joint steering committee to coordinate all scientific matters of the collaboration.

“We are thrilled to announce the strategic research collaboration with TransThera to explore new drugs for GI and liver disease field.” said Masafumi Minomura, Managing Director of R&D at EA Pharma, “Based on our original and unique drug discovery platform, we are excited to embark on a path for innovation together with innovative and dynamic TransThera with expertise in immunology, and through this collaboration we firmly believe that we can paint a bright picture of developing new therapies for GI and liver disease patients.”.

“This is an exciting opportunity for TransThera to work with EA Pharma as a global partner who shares our commitment to bringing transformative therapies to patients with highly unmet medical need.” said Dr. Frank Wu, Founder and CEO of TransThera. “Immunology is a key area of focus for TransThera. We have a deep understanding of the complex biology of inflammatory diseases and an effective "ACE" (an acronym of Adaptive, Comprehensive and Expandable) platform for the discovery and optimization of novel small molecular medicines. Leveraging the strength of both companies in the drug innovation, we hold a strong belief that this collaboration will expedite the discovery process of novel therapies for patients.”.